<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691570</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-wAIHA-02</org_study_id>
    <nct_id>NCT04691570</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)</brief_title>
  <official_title>A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of ANX005 in participants with Warm&#xD;
      Autoimmune Hemolytic Anemia (wAIHA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed of study details and potential risks, all participants who provide&#xD;
      written informed consent will undergo a 6-week screening period to determine eligibility.&#xD;
      Participants who meet the eligibility criteria will receive two once-weekly intravenous (IV)&#xD;
      infusions of ANX005 in the clinic. Participants will return to the clinic weekly through Week&#xD;
      10 for study assessments. The total duration of individual participation in this study may be&#xD;
      up to 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Number of participants with TEAEs, defined as any adverse event with an onset on or after the day of infusion through 16 weeks after the infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>Up to Day 71</time_frame>
    <description>Plasma concentrations of ANX005 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in complement system biomarkers</measure>
    <time_frame>Baseline to Day 71</time_frame>
    <description>Change in CH50 and C1q from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity biomarkers</measure>
    <time_frame>Baseline to Day 71</time_frame>
    <description>Change in hemoglobin, lactate dehydrogenase, bilirubin, and haptoglobin from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Warm Autoimmune Hemolytic Anemia (wAIHA)</condition>
  <arm_group>
    <arm_group_label>ANX005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two once-weekly doses of ANX005 at specific time points</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>ANX005 is provided as a solution for IV infusion</description>
    <arm_group_label>ANX005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female ≥18 years of age (no maximum age).&#xD;
&#xD;
          -  Diagnosis of wAIHA at least 3 months prior to screening.&#xD;
&#xD;
          -  Hemoglobin (Hgb) level &lt;10.0 g /dL (pre-transfusion).&#xD;
&#xD;
          -  Positive direct antiglobulin test (DAT) ≥ 1+ for C3d and immunoglobulin G (IgG).&#xD;
&#xD;
          -  Evidence of classical complement pathway activation.&#xD;
&#xD;
          -  CH50 below the lower limit of normal.&#xD;
&#xD;
          -  Evidence of active hemolysis.&#xD;
&#xD;
          -  Stable use of glucocorticoids and immunosuppressants are permitted.&#xD;
&#xD;
          -  Vaccinations against encapsulated bacterial organisms within 5 years prior to&#xD;
             screening or participant must be willing to complete vaccinations at least 2 weeks&#xD;
             prior to dosing with ANX005.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Elevated aspartate aminotransferase or alanine aminotransferase levels &gt;2.5 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          -  Platelet count &lt; 30 X 10^9/L.&#xD;
&#xD;
          -  History of cold agglutinin disease.&#xD;
&#xD;
          -  History of solid organ, bone marrow, or stem cell transplantation.&#xD;
&#xD;
          -  History of splenectomy within the 3 months prior to screening.&#xD;
&#xD;
          -  Received rituximab or other anti-CD20 monoclonal antibody &lt;3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Intravenous immunoglobulin (IVIg) treatment within 3 months prior to screening or&#xD;
             plasmapheresis or immunoadsorption treatment within 60 days prior to screening.&#xD;
&#xD;
          -  Clinically significant, recent, or ongoing illness or medical condition, including&#xD;
             coexistent autoimmune disorder, malignancy, HIV, hepatitis B virus, and hepatitis C&#xD;
             virus.&#xD;
&#xD;
          -  History of meningitis or septicemia within the past 2 years.&#xD;
&#xD;
          -  Treatment with an investigational therapeutic agent within 30 days prior to screening.&#xD;
&#xD;
          -  Hypersensitivity to any drug product or excipients used in this study or to previous&#xD;
             IV medication administration.&#xD;
&#xD;
          -  Body weight less than 50 kg or greater than 100 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morie Gertz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Rochester, MN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>650-822-5500</phone>
    <email>clinicaltrials@annexonbio.com</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIHA</keyword>
  <keyword>C1q</keyword>
  <keyword>complement</keyword>
  <keyword>RBC lysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

